FindDrugs.org

MEDVi Review

Brand-level review · Last reviewed Sep 23, 2026

5.50/10

Operator-trust score

The brand-level factors every category shares — legitimacy, clinical oversight, transparency, privacy, policy, support — not price or per-treatment value.

Clinician accessFastest startCash-pay

Our verdict

MEDVi is a cash-pay telehealth brand selling compounded semaglutide and tirzepatide while outsourcing both the clinical work and the compounding to third parties. Its operator-trust score is 5.50 — the brand-level factors every category shares, not price or per-treatment value. Its weak points are disclosure and record rather than reach: it publishes neither who prescribes nor who compounds on its own pages, and no price at all before signup. A February 2026 FDA warning letter citing misbranding is on the record, alongside a breach at its infrastructure partner OpenLoop affecting roughly 716,000 individuals on the federal register.

MEDVi plans & reviews by category

Each category is scored separately. Read the full review where one exists — or check current pricing directly.

Weight Loss / GLP-1

5.36/10
Read the Weight Loss / GLP-1 reviewCheck price
  • Semaglutide · injection$299/mo
  • Tirzepatide · injection$399/mo
  • Tirzepatide · oral$279/mo

Prices as of Sep 23, 2026 — verify current on the brand's site.

Key takeaways

  • Accreditation flows through its partners rather than through MEDVi itself; what those partners list is company-attested and could not be checked against the issuing registers, and MEDVi's own licensure could not be established either way.
  • An FDA warning letter (#721455, 2026-02-20) citing misbranding violations is on the record.
  • Publishes no retrievable price on its own site: its GLP-1 page renders pricing as unfilled template placeholders, and the cost is not disclosed before signup.
  • Does not disclose who compounds or who prescribes on its own pages.
  • A breach at its infrastructure partner OpenLoop, which handles MEDVi patient data, affected roughly 716,000 individuals on the HHS OCR register.
  • Publishes neither the states it serves nor its shipping terms, so access speed could not be established from any source that originates the fact.
  • Its refund conditions and cancellation window are not stated on its own pages; the terms previously reported came from a commission-earning third party and could not be confirmed against the brand.

What is MEDVi?

MEDVi is a direct-to-consumer telehealth brand focused on GLP-1 weight management, and it runs neither the clinical nor the pharmacy side of that itself. Licensed US physicians review intake through networks such as OpenLoop and CareValidate; medications are compounded by Belmar Pharma Solutions, with oral tablets reportedly filled by Triad Rx; the regulatory classifications those pharmacies hold are company-attested and could not be checked against the issuing registers. It operates on a cash-pay basis in one category, weight management. It does not publish which states it serves, and the compounded medications it sells are not individually FDA-approved.

Is MEDVi legit?

Qualified. MEDVi is a real operating telehealth company using licensed US physicians and an accredited compounding partner in Belmar, but the accreditation belongs to those partners rather than to MEDVi itself, and MEDVi’s own licensure could not be established either way. A February 2026 FDA warning letter for misbranding is on the record.

  • Licensed & accredited: Accreditation flows through partners rather than MEDVi itself; we could not verify the partner accreditations, and MEDVi's own licensure could not be established either way; a Feb 2026 FDA misbranding letter (marketing-type, part of a 30+ company wave) is on record — FDA warning letter (fda.gov), Feb 2026.
  • Clinician model: Licensed U.S. physicians via the OpenLoop/CareValidate networks review intake and are now identifiable, though oversight is outsourced and asynchronous — DrugDiscoveryTrends, Jul 2026.
  • Medication & pharmacy: Belmar is named as the compounder, with oral tablets filled by a separate pharmacy (Triad Rx); the accreditations Belmar lists are company-attested and could not be checked against the issuing registers, and which pharmacy fills what is not clearly disclosed — MEDVi (medvi.io), Jul 2026.
  • Watch-outs: A pending class action questioning the efficacy of compounded oral tirzepatide is on record — MedicalFoundationOfNC, Jul 2026.

Treatment options

What MEDVi actually treats. Pricing lives in the plans table above and in each category review.

  • Weight loss (GLP-1)

    compounded semaglutide and tirzepatide by injection, and compounded tirzepatide tablets

Pros & cons

Pros

  • Transparent, publicly listed cash-pay pricing competitive vs brand-name GLP-1s
  • Compounding partner Belmar lists accreditations on its own site — company-attested, not independently confirmed
  • Fast access: async intake reviewed in 24-48h
  • Month-to-month with a stated 5-month money-back guarantee (75% refund)
  • High Trustpilot volume (~11,400 reviews) averaging ~4.4/5

Cons

  • Feb 20, 2026 FDA warning letter for misbranding
  • Reported AI-generated fake ads, reviews, and doctor testimonials (MEDVi attributes them to an affiliate marketer)
  • Clinical and pharmacy roles are not clearly disclosed
  • ~716K-individual data breach at infrastructure partner OpenLoop (Jan 2026; HHS OCR portal)
  • Pending class action alleging compounded oral tirzepatide lacks demonstrated efficacy

The bottom line

MEDVi suits price-sensitive shoppers who want speed and are comfortable with a fully outsourced, questionnaire-based model. Anyone who wants to know the price before signing up, or to know who is prescribing and who is compounding, should look elsewhere.

What changed & why

This brand's own history — every re-review and methodology recompute, logged. Rankings change when the evidence or the rules change, never for payment. See the site-wide methodology ledger for version history.

  1. Sep 18, 2026Initial score5.50

    MEDVi's Operator Trust Score first recorded at 5.50 out of 10 — the earliest score in this log.

Review score changes

The timeline above is this brand's Operator Trust Score. Each review below is scored separately, and keeps its own history.

  • Weight Management / GLP-1 review— last changed Sep 14, 2026See changes

Work at MEDVi?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Completeness was not recorded for this score · 3 sources cited

Regulatory

Other

What we couldn't verify

  • getmedvi.com could not be fetched directly (TLS cert expired); on-site pricing/eligibility corroborated via aggregators and medvi.io.
  • Trustpilot now verified at 4.4/14,176 (rendered fetch 2026-07-24); face value still discounted for documented AI/fake reviews.
  • Exact refill pricing for oral tablets and multi-month prepay tiers not consistently published.
  • Precise split of which pharmacy fills each product/format not clearly disclosed.
  • Withdrawn — MEDVi's prices ($179 first month / $299 monthly refills). MEDVi's prices ($179 first month / $299 monthly refills) are WITHDRAWN. The figures rested solely on weightlossproviderguide.com, which discloses that it "may earn a commission if you sign up through links on this page" and which states it took the figures from medvi.org. MEDVi's own pages render price as unfilled template variables (${seminject_sale_price}) and publish no dollar figure (glp1.medvi.org and home.medvi.org, both fetched 2026-08-10).
  • Withdrawn — MEDVi's cancellation terms (72-hour notice) and refund conditions (five months without weight loss, minus a 25% consultation fee). MEDVi's cancellation terms (72-hour notice) and refund conditions (five months without weight loss, minus a 25% consultation fee) are WITHDRAWN — affiliate-page sourcing only, and home.medvi.org publishes neither a cancellation window nor refund conditions (fetched 2026-08-10).
  • Withdrawn — MEDVi's states-served claim ("49 states, excludes North Dakota") and free-shipping claim. MEDVi's states-served claim ("49 states, excludes North Dakota") and free-shipping claim are WITHDRAWN — affiliate-only sourcing; neither home.medvi.org nor glp1.medvi.org states which states are served (fetched 2026-08-10).
  • Withdrawn — MEDVi's "$401 million in 2025 revenue, independently verified by The New York Times". MEDVi's "$401 million in 2025 revenue, independently verified by The New York Times" is WITHDRAWN. The only source was medicalfoundationofnc.org — which discloses affiliate commission, bylines its work to an unnamed "Editorial Team", and attributes the figure to the NYT WITHOUT naming or linking the article (fetched 2026-08-10). Neither we nor the intermediary retrieved the Times.
  • policy-clarity-fairness: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. MEDVi's home page LINKS a refund policy — so it does disclose, and the terms exist somewhere we did not reach. Every candidate URL we tried 404s. That is retrieval failure against a document the brand demonstrably publishes; scoring 30 for it would penalise MEDVi for a page we could not find.
  • access-speed: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. States-served is absent from the two pages we fetched, but we found no states or coverage page to check, and absence from a landing page is not absence from the site. Unclear → excluded, per the asymmetry rule.
  • popularity-momentum: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. The withdrawn item was a $401m revenue figure attributed to the NYT by an affiliate page that never linked the article. That is purely OUR sourcing failure, and no company is obliged to publish revenue — there is no disclosure to be absent. Marking MEDVi down 85→55 for it was the clearest instance of the defect this pass exists to undo.
  • Withdrawn — MEDVi advertising used fictitious personas, and that its founder acknowledged AI-generated website content,. The claim that MEDVi advertising used fictitious personas, and that its founder acknowledged AI-generated website content, is WITHDRAWN to gaps[]. It rested on a single trade-press investigation, which fails ORIGINATOR, and no primary record exists — attributing it ("Drug Discovery Trends reports…") is not sourcing. Withdrawn for want of a primary source, not disproved. (2026-08-11)
  • Withdrawn — MEDVi "owns no pharmacy, employs no physicians and holds no drug licenses". The claim that MEDVi "owns no pharmacy, employs no physicians and holds no drug licenses" is WITHDRAWN. One registry attempt was made on 2026-08-11 as ruled: NABP's accredited-pharmacy directory returned HTTP 403 to us, and openFDA's drugsfda endpoint is a record of drug approvals rather than pharmacy licensure, so a null result there is not evidence. Absence of a record in a registry we cannot query is not a record of absence — that is retrievalFailed, not an authoritative negative. Withdrawn, not disproved. (2026-08-11)
Last reviewed Sep 23, 2026View the ledger